Seneca Partners, the specialist SME investment business based in the North-West, has reported that the Seneca Growth Capital VCT has delivered a NAV B share increase from 91.8p to 104.6p in the first six months of the year.
This demonstrates the continued positive momentum for the VCT over the last 15 months, which has seen the NAV per B share increase by 31.6% since March 2020.
Matt Currie, Investment Director at Seneca Partners commented; “We are pleased that the Seneca Growth Capital VCT continues to achieve positive momentum on the back of growth and realisations in our AIM-quoted investments, such as Skin Biotherapeutics and Polarean Imaging.
“To capitalise on our track record of AIM investing, we have recently announced the launch of the Seneca AIM EIS Fund, which allows investors to benefit from the inherent tax advantages of both VCTs and EIS.”
The value of an investment may go down as well as up, in which case an investor may not get back the amount invested. Past performance is not a guide to future performance. Investors should seek advice from a qualified financial adviser. Nothing on this website should be construed as investment or tax advice.